Acute Interstitial PneumoniaSymptoms, Doctors, Treatments, Advances & More
Acute Interstitial Pneumonia Overview
Learn About Acute Interstitial Pneumonia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Taubman Center
Director of the Michigan Medicine Interstitial Lung Disease program, Vice-Chair of the Medical School Institutional Review Board for Human Subjects Research, Associate Program Director Internal Medicine Residency Program - Research, Co-Director University of Michigan Medical School Scientific Discovery Pathway, Steering committee chair for the pulmonary fibrosis foundations Care Center Network and Patient Registry. Dr. Flaherty is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Flaherty is board certified in Pulmonary Disease.
UPMC Comprehensive Lung Center - Simmons Center
Kevin Gibson, MD, specializes in interstitial lung disease and is board-certified in pulmonary disease and internal medicine by the American Board of Internal Medicine. He practices at UPMC Comprehensive Lung Center - Simmons Center and is affiliated with University of Pittsburgh Physicians, Department of Medicine and UPMC Presbyterian. Dr. Gibson completed his medical degree at University of Medicine and Dentistry of New Jersey, residency at Emory University School of Medicine, and fellowship at the University of Pittsburgh School of Medicine.Dr. Gibson specializes in treating patients with idiopathic pulmonary fibrosis, sarcoidosis, autoimmune lung disease, and occupational lung disease. Dr. Gibson is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Lung Transplant. Dr. Gibson is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Gibson is currently accepting new patients.
Inova Medical Group - Transplant Specialties
Oksana A. Shlobin, MD, FCCP, serves as Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. She is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine and an Associate Clinical Professor of Medicine at the University of Virginia. Dr. Shlobin is board certified in pulmonary and critical care medicine. Dr. Shlobin has been actively involved in clinical research both during her fellowship and her tenure at Inova. She is co-author of multiple publications, including original research manuscripts, abstracts and book chapters. Her research interests include pulmonary hypertension and interstitial lung diseases. Blog Posts What is Pulmonary Hypertension? Learn the Facts to Breathe Easy (November 2018) Pulmonary Hypertension is Serious. Learn to Spot the Signs (May 2017). Dr. Shlobin is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy.
Summary: MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see if low doses of the hormone drug danazol can help.


